Fig. 1: Lineage specific chimerism and patient’s clinical response. | Bone Marrow Transplantation

Fig. 1: Lineage specific chimerism and patient’s clinical response.

From: Durable remission of refractory and advanced stage mycosis fungoides/sezary syndrome utilizing an “outpatient” alemtuzumab, fludarabine-based reduced intensity allogeneic hematopoietic cell transplantation

Fig. 1

a Lineage specific chimerism of each subject. T-cell and myeloid chimerism were determined by PCR analysis of short tandem repeat (STR) on day 15, 30, 45, 60, 100, and continued monthly until full donor chimerism was achieved in both lineages. Complete donor chimerism was defined as >95% donor derived cells in peripheral blood in a specific lineage. b Patient #2 who achieved a long-lasting remission of stage 3 mycosis fungoides following alemtuzumab/Fludarabine based RIC allogeneic hematopoietic stem cell transplantation. Serial post-transplant photographs show (a) biopsy-confirmed MF tumor nodules that persisted 1 month after HCT (b) becoming hyperkeratotic, macular and smaller in size following CSA tapering at 7-month post HCT; (c) 5 years after HCT, the patient remained in remission with normal appearing skin without any evidence of cGVHD.

Back to article page